Overview
Gene‑based technologies are being touted as a way to curb malaria, dengue and other vector‑borne diseases. The core idea is to insert a gene drive into mosquitoes so that the trait spreads rapidly. Advances in CRISPR/Cas9 have turned this concept from theory to practice. However, the technology raises ecological, biosafety and governance questions that India and the world must address before field release.
Key Developments
- 2003: Evolutionary biologist Austin Burt proposed the theoretical basis of super‑Mendelian inheritance.
- Recent years: Laboratory‑tested drives that either suppress mosquito populations or render them resistant to Plasmodium parasites.
- Emerging designs such as daisy‑chain drives, reversal drives and split‑drive systems aim to improve safety.
- International bodies – the WHO and the U.S. National Academies of Sciences – have drafted phased testing frameworks that stress ecological data and community consent.
Important Facts
• A single infected mosquito can transmit malaria to dozens of people; a single gene can spread through the mosquito population over several generations.
• Natural transposable elements illustrate how genetic material can selfishly replicate, but host resistance usually limits damage.
• Engineered drives differ from natural drivers because they are designed to spread faster and for a specific purpose, such as population suppression or pathogen resistance.
Exam Relevance
Understanding gene drives touches upon several GS papers: GS3 – Environment and Ecology (impact on biodiversity, invasive species, bio‑control), GS2 – Polity (regulatory frameworks, international guidelines), and GS4 – Ethics (risk‑benefit analysis, public consent). Questions on biotechnology governance, biosafety, and the role of international agencies frequently appear in the prelims and mains.
Way Forward
1. Risk‑Benefit Assessment: Quantify lives saved versus ecological disruption. Compare with existing tools like insecticide‑treated nets.
2. Regulatory Preparedness: Adopt the phased testing model of WHO and the U.S. Academies. Ensure Indian bodies (DBT, MoEFCC) coordinate ecological studies and obtain community consent.
3. Containment Technologies: Prioritise self‑limiting designs (daisy‑chain, split‑drive) and develop reversal drives to undo unintended spread.
4. Public Engagement: Conduct awareness campaigns to address ethical concerns and build trust among affected communities.
5. International Collaboration: Share data with global partners to create a common safety net and avoid unilateral releases.
By balancing scientific promise with robust governance, India can harness gene‑drive technology responsibly while safeguarding its ecosystems and public health.